Joy For SMA Patients As NICE And Biogen Break Spinraza Deadlock
Executive Summary
Between 600-1,200 people in England and Wales may be able to get Spinraza now that after 17 months of negotiations "appropriate flexibility" has led to an access agreement.
You may also be interested in...
Novartis’s Zolgensma In Spotlight As Second Death Is Probed
Reports of patient deaths could raise questions around safety for Novartis's gene therapy Zolgensma which is expected to get the green light imminently from the FDA.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.